HLTH22: Rimidi Launches New Respiratory Module to Deliver Better Treatment

💡 This post was automatically imported from HIT Consultant. You can find the original article here.
Author: HIT Consultant Media (Jasmine Pennic)

What You Should Know:

Rimidi launches its new Respiratory Module through integration with Teva Pharmaceuticals’ digital inhalers that be integrated into healthcare provider workflows, enhancing respiratory care and population health management.

– This new module allows providers to comprehend the full picture of the patient’s disease status both in the clinic and at home – giving clinical teams the tools they need to make personalized, predictive care decisions and improve outcomes.

Why It Matters

Over 500 million people globally suffer from respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In many cases, patients with these respiratory conditions also have cardiometabolic disorders like hypertension, obesity and diabetes, which can create additional health complications and lead to greater healthcare expenses. Rimidi’s Respiratory Module, which complements the company’s full suite of disease modules, allows providers to comprehend the full picture of the patient’s disease status both in the clinic and at home. As a result, staff are better empowered and equipped to make personalized, predictive care decisions and improve outcomes.

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics.

You may also like...

Welcome to MediFormatica. The site is still under construction so there are some rough edges here and there, but I'll be adding new and exciting content every day. So enjoy it and come back again for more great stuff.

X